White House not giving up on TV ad drug price rule

22 August 2019

US President Donald Trump is reviving a stalled effort to compel drugmakers to list drug prices in direct to consumer (DTC) advertising, after a court struck down the initiative.

On Wednesday, the US Department of Health and Human Services (HHS) filed a notice of appeal against a federal court ruling from July, which granted a request to vacate the rule from appellants including Eli Lilly (NYSE: LLY) and Merck & Co (NYSE: MRK).

In 2018, the White House sought to force companies to include the list price of products on TV adverts, despite objections from leading US pharma trade group PhRMA, Pharmaceutical Research and Manufacturers of America.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK